{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["22(1)"],"submitter":["Rudman Spergel AK"],"pubmed_abstract":["A multicomponent vaccine against seasonal influenza and COVID-19 could reduce disease burden in adults by providing simultaneous protection in a single-dose regimen. The first-generation, mRNA-based, multicomponent mRNA-1073 vaccine, combining antigens encoded by mRNA-1010 (influenza) and mRNA-1273 (COVID-19) vaccines, was investigated in a phase 1/2 clinical trial. This stratified, observer-blinded study randomly assigned healthy adults (18-75 years) to receive mRNA-1073 (25-µg, 50-µg, or 100-µg) + placebo, mRNA-1273 (50-μg) + placebo, mRNA-1010 (50-μg) + placebo, or co-administered mRNA-1010 (50-μg) + mRNA-1273 (50-μg) on day 1. Primary study objectives were safety and reactogenicity. Secondary study objectives assessed humoral immunogenicity against vaccine-matched influenza and SARS-Co"],"journal":["Human vaccines & immunotherapeutics"],"pagination":["2589644"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12867370"],"repository":["biostudies-literature"],"pubmed_title":["Phase 1/2 randomized, observer-blind clinical trial of a first-generation, mRNA-based vaccine against seasonal influenza and COVID-19 in healthy adults."],"pmcid":["PMC12867370"],"pubmed_authors":["Shih-Lu-Lee J","Carmona L","Ananworanich J","Henry C","Rudman Spergel AK","Brune D","Avanesov A","Embry A","Nachbagauer R","Cizmeci D","Guo R","Irfan M","Yu WH","Astley E","Bertera H","Alter G","Collins A","Kaplonek P","Mao X","Shaw CA","Chu L","Pucci A","Shao S"],"additional_accession":[]},"is_claimable":false,"name":"Phase 1/2 randomized, observer-blind clinical trial of a first-generation, mRNA-based vaccine against seasonal influenza and COVID-19 in healthy adults.","description":"A multicomponent vaccine against seasonal influenza and COVID-19 could reduce disease burden in adults by providing simultaneous protection in a single-dose regimen. The first-generation, mRNA-based, multicomponent mRNA-1073 vaccine, combining antigens encoded by mRNA-1010 (influenza) and mRNA-1273 (COVID-19) vaccines, was investigated in a phase 1/2 clinical trial. This stratified, observer-blinded study randomly assigned healthy adults (18-75 years) to receive mRNA-1073 (25-µg, 50-µg, or 100-µg) + placebo, mRNA-1273 (50-μg) + placebo, mRNA-1010 (50-μg) + placebo, or co-administered mRNA-1010 (50-μg) + mRNA-1273 (50-μg) on day 1. Primary study objectives were safety and reactogenicity. Secondary study objectives assessed humoral immunogenicity against vaccine-matched influenza and SARS-Co","dates":{"release":"2026-01-01T00:00:00Z","publication":"2026 Dec","modification":"2026-07-15T11:49:41.476Z","creation":"2026-07-06T03:08:40.828Z"},"accession":"S-EPMC12867370","cross_references":{"pubmed":["41627968"],"doi":["10.1080/21645515.2025.2589644"]}}